Market Research Logo

Retinopathy - Pipeline Review, H1 2016

Retinopathy - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Retinopathy - Pipeline Review, H1 2016’, provides an overview of the Retinopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinopathy
  • The report reviews pipeline therapeutics for Retinopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Retinopathy therapeutics and enlists all their major and minor projects
  • The report assesses Retinopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Retinopathy
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Retinopathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Retinopathy Overview
Therapeutics Development
Pipeline Products for Retinopathy - Overview
Pipeline Products for Retinopathy - Comparative Analysis
Retinopathy - Therapeutics under Development by Companies
Retinopathy - Therapeutics under Investigation by Universities/Institutes
Retinopathy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Retinopathy - Products under Development by Companies
Retinopathy - Products under Investigation by Universities/Institutes
Retinopathy - Companies Involved in Therapeutics Development
Acucela Inc.
Biomar Microbial Technologies
Biophytis SAS
Edison Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Insmed Incorporated
Navigen Pharmaceuticals, Inc.
RedHill Biopharma Ltd.
Retinopathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABC-294640 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
emixustat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IB-09A0133 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IB-12A157 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mecasermin rinfabate (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAV-2729 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Oncology and Ophthalmology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Retinopathy of Prematurity - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Eya Tyrosine Phosphatase for Solid Tumors and Retinopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vatiquinone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinopathy - Recent Pipeline Updates
Retinopathy - Dormant Projects
Retinopathy - Discontinued Products
Retinopathy - Product Development Milestones
Featured News & Press Releases
Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants
Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Retinopathy, H1 2016
Number of Products under Development for Retinopathy - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Retinopathy - Pipeline by Acucela Inc., H1 2016
Retinopathy - Pipeline by Biomar Microbial Technologies, H1 2016
Retinopathy - Pipeline by Biophytis SAS, H1 2016
Retinopathy - Pipeline by Edison Pharmaceuticals, Inc., H1 2016
Retinopathy - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Retinopathy - Pipeline by Insmed Incorporated, H1 2016
Retinopathy - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016
Retinopathy - Pipeline by RedHill Biopharma Ltd., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Retinopathy Therapeutics - Recent Pipeline Updates, H1 2016
Retinopathy - Dormant Projects, H1 2016
Retinopathy - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Retinopathy, H1 2016
Number of Products under Development for Retinopathy - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report